These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1563378)

  • 41. Penetration of ceftazidime into human pancreas.
    Drewelow B; Koch K; Otto C; Franke A; Riethling AK
    Infection; 1993; 21(4):229-34. PubMed ID: 8225626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis.
    Davies SP; Lacey LF; Kox WJ; Brown EA
    Nephrol Dial Transplant; 1991; 6(12):971-6. PubMed ID: 1798597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites.
    el Touny M; el Guinaidy MA; Abd el Barry M; Osman L; Sabbour MS
    J Antimicrob Chemother; 1991 Jul; 28(1):95-100. PubMed ID: 1769947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous infusion of ceftazidime with an elastomeric infusion device.
    Couldry R; Sanborn M; Klutman NE; Strayer AH
    Am J Health Syst Pharm; 1998 Jan; 55(2):145-9. PubMed ID: 9465978
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of ceftazidime in elderly patients and young volunteers.
    Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 1984; 16(3):325-6. PubMed ID: 6387894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan.
    Saito A
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():255-62. PubMed ID: 6352628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Penetration of ceftazidime into the human prostate gland following intravenous injection.
    Abbas AM; Taylor MC; Da Silva C; Francis RA; Bennet C
    J Antimicrob Chemother; 1985 Jan; 15(1):119-21. PubMed ID: 3882653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single- and multiple-dose pharmacokinetics of ceftazidime in infected patients with varying degrees of renal function.
    Lin MS; Wang LS; Huang JD
    J Clin Pharmacol; 1989 Apr; 29(4):331-7. PubMed ID: 2656776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine.
    Benchaoui HA; Nowakowski M; Sherington J; Rowan TG; Sunderland SJ
    J Vet Pharmacol Ther; 2004 Aug; 27(4):203-10. PubMed ID: 15305848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia.
    Cousson J; Floch T; Guillard T; Vernet V; Raclot P; Wolak-Thierry A; Jolly D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1905-9. PubMed ID: 25583727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of ceftazidime in patients with biliary tract disease.
    Walstad RA; Wiig JN; Thurmann-Nielsen E; Halvorsen TB
    Eur J Clin Pharmacol; 1986; 31(3):327-31. PubMed ID: 3539624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
    van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
    Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding.
    Hedaya MA; Daoud SS
    Anticancer Res; 2001; 21(6A):4005-10. PubMed ID: 11911284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dosage adjustment for ceftazidime in patients with impaired renal function.
    van Dalen R; Vree TB; Baars AM; Termond E
    Eur J Clin Pharmacol; 1986; 30(5):597-605. PubMed ID: 3530782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distribution of ceftazidime in ascitic fluid.
    Benoni G; Arosio E; Raimondi MG; Apolloni E; Passarella E; Lechi A; Velo GP
    Antimicrob Agents Chemother; 1984 Jun; 25(6):760-3. PubMed ID: 6378086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability.
    Bressolle F; de la Coussaye JE; Ayoub R; Fabre D; Gomeni R; Saissi G; Eledjam JJ; Galtier M
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1404-11. PubMed ID: 1510435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
    Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
    J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.